Rhonda Dixon
Family · Conway, ARNPI 1700207339
Payments from drug & device makers
Across 79 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$227
- Lilly USA, LLC$209
- AstraZeneca$149
- Pfizer$135
- Abbott$123
- Novo Nordisk$106
- plus $455 from 12 others
What the payments were for
- Food & beverage$1,405100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $227 |
| Lilly USA, LLC | 13 | $209 |
| AstraZeneca | 9 | $149 |
| Pfizer | 7 | $135 |
| Abbott | 7 | $123 |
| Novo Nordisk | 6 | $106 |
| AbbVie | 5 | $98 |
| Boehringer Ingelheim | 4 | $81 |
| Dexcom, Inc. | 3 | $53 |
| Exact Sciences | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Amgen | 2 | $34 |
| Astellas Pharma US Inc | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$1,405 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 114 | $117,574 |
| OzempicSemaglutide | 72 | $96,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $77,605 |
| EliquisApixaban | 93 | $75,331 |
| JardianceEmpagliflozin | 45 | $48,612 |
| FarxigaDapagliflozin Propanediol | 29 | $23,693 |
| TrulicityDulaglutide | 20 | $19,604 |
| EntrestoSacubitril/Valsartan | 18 | $17,217 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $9,174 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,938 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,752 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,502 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 255 | $6,212 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $4,773 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $209 | $137,178134 claims |
| Novo NordiskOzempic, Levemir | $106 | $97,82486 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $227 | $95,717135 claims |
| PfizerEliquis | $135 | $75,33193 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $81 | $56,11459 claims |
| AstraZenecaFarxiga, Symbicort | $149 | $31,44450 claims |
| AbbVieSynthroid | $98 | $2,04752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.
Other family in Conway
- Meghan MallettConway$25K
- Sheila ForresterConway$17K
- Elana RussellConway$17K
- Donald KulbethConway$12K
- Kayla JohnsonConway$9K
- Crystal BrownConway$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.